PresseMitteilungen zu dem Schlagwort immunoassay
20 years of radioimmunoassays for diabetes diagnostics - Why should radioactive test reagents still be used in diagnostics, as nowadays more and more people disapprove radioactive technology? To put it simple: many areas of modern medicine would not be possible without the use of radioactive treatments, and in the field of diagnostics there are many radioactive test reagents that are still recognized as gold standard methods. Today the number of companies still offering radioimmunoassay (RIA) r ...
MISSISSAUGA, ON -- (Marketwired) -- 10/05/15 -- CardioGenics Holdings Inc. (OTCQB: CGNH), developer of the ultra-sensitive QL Care™ analyzer, an immunoassay point-of-care analyzer, and other products for the In-Vitro-Diagnostics ("IVD") testing market, announced today that it has entered into a binding letter of intent to acquire substantially all of the assets of Plasticap ("LOI). CardioGenics previously announced on August 25, 2015 that it had entered into a manufacturing agree ...
CANDOR expands its broad selection of premium solutions for immunoassays with ReadyTector®, the all-in-one Solution for Western blotting. With ReadyTector® the originator of LowCross-Buffer® expands its selection beyond ELISA products. The development of this innovative solution for quick Western blotting is based on the specific CANDOR know-how in the area of immunoassays. ReadyTector® accelerates and simplifies immunodetection on Western blot membranes. Blocking and immunodetection are carrie ...
R-Biopharm, a global leader in providing innovative clinical diagnostics, enters into a strategic alliance with CANDOR Bioscience GmbH (Wangen, Allgäu, Germany), effective immediately. R-Biopharm has its own corporate division for companion diagnostics (CDx), i.e. diagnostics concomitant to therapy, as well as for complementary diagnostics. There, R-Biopharm is at the spearhead of the current development of tests for new approaches in personalized medicine. R-Biopharm will further expand its p ...
MISSISSAUGA, ON -- (Marketwired) -- 11/04/15 -- CardioGenics Holdings Inc. (OTCQB: CGNH), developer of the ultra-sensitive QL Care™ analyzer, an immunoassay point-of-care analyzer, and other products for the In-Vitro-Diagnostics ("IVD") testing market, announced today that it, and its newly created Canadian subsidiary, have entered into a definitive asset purchase agreement to acquire substantially all of the assets of Plasticap. CardioGenics previously announced on October 5, 2015 th ...
| All members: | 9 438 |
| Register today: | 0 |
| Register yesterday: | 0 |
| Members online: | 0 |
| Guests online: | 61 |
Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.
